New Jersey, USA-based Alvogen Group says that it has acquired R&D capabilities from Par Pharmaceutical. .As part of the agreement, Alvogen and Par have entered into a multi-year agreement for the development of several high-value, first-to-file generic product opportunities.
The acquisition provides Alvogen with internal R&D capabilities for the development of important new generic drugs. It also enables the company to develop many additional products internally, and adds to the rapidly growing product pipeline of over 40 products. Alvogen's internal product development capabilities will mainly focus on the development of difficult to replicate generic drugs with high barriers to entry, the company says.
With a current pipeline of over 40 solid dose, controlled release and transdermal patch products for the US market, Alvogen's initial pipeline will target branded products with annual sales in excess of $17 billion. Alvogen says it has full-service Rx production capabilities in a state-of-the-art 8 billion tablet, 375,000 square feet facility with an exceptional reputation for quality, located in Norwich, NY.
Commenting on the transaction, Doug Drysdale, Chief Executive Officer of Alvogen said: 'The expansion of our internal product development to pursue high-value first-to-file opportunities builds on our strong existing pipeline of complex generic products. We have built an excellent working relationship with the team at Par and are looking forward to collaborating on these high-potential projects.'
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze